Brookline Capital Markets analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ: RADX) with a Buy rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE